1. Japan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Daiken Medical Co., Ltd.

Daiken Medical Co., Ltd.

TTSE:7775
423.00
JPY
-2.00
(-0.47%)
12.87BMarket Cap
Oct 30Next Earn
Daiken Medical Co., Ltd.
TSE:7775
(Tokyo Stock Exchange)

Recent

price

423.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
212.83
220.54
238.08
252.82
266.07
275.47
280.07
286.64
286.78
296.69
273.67
297.28
318.05
339.39
346.41
358.22
- -
Revenue per Share
18.92
13.68
26.53
29.19
36.36
38.45
41.55
33.79
29.05
29.92
23.5
28.93
24.79
34.41
38.21
32.12
- -
Basic EPS, GAAP
23.07
-0.05
36.93
27.53
25.15
-0.66
24.62
20.62
22.98
44.13
10.34
32.39
27.5
48.27
33.18
8.35
- -
Free Cash Flow per Basic Share
4.2
5.46
5.73
16.54
12.17
16
16.02
27.02
26.38
19.01
20.01
19.99
19.68
19.98
21.33
22.98
- -
Dividend per Share
140.67
148.65
168.69
181.71
194.76
217.15
242.73
222.97
200.77
211.69
215.2
224.38
229.64
244.44
261.62
270.72
- -
Book Value per Share
137.71
145.16
165.77
178.63
192.04
214.88
240.67
221.44
199.65
210.67
214.44
223.85
229.31
243.97
261.17
269.94
- -
Tangible Book Value per Share
29
30
30
30
30
30
30
30
29
29
29
29
29
29
29
29
29
Basic Weighted Avg Shares
6,242
6,515
7,068
7,636
8,033
8,261
8,400
8,585
8,407
8,523
7,862
8,540
9,137
9,750
9,952
10,291
- -
Sales/Revenue/Turnover
15.61
15.57
17.84
18.2
20.19
20.53
20.37
17.54
14.86
14.01
11.72
13.48
11.54
14.8
15.19
12.41
- -
Operating Margin (%)
303
302
250
189
155
184
176
251
303
253
257
314
267
214
233
258
- -
Depreciation Expense
555
404
788
881
1,098
1,153
1,246
1,012
852
860
675
831
712
989
1,098
923
- -
Net Income, GAAP
39.36
59.68
37.11
36.26
31.43
32.29
26.6
25.71
26.18
27.84
28.53
27.82
30.53
31.18
27.23
25.96
- -
Effective Tax Rate (%)
8.89
6.2
11.14
11.54
13.67
13.96
14.83
11.79
10.13
10.08
8.59
9.73
7.79
10.14
11.03
8.97
- -
Profit Margin (%)
2,423
2,665
3,112
3,215
3,338
3,543
3,088
3,346
2,640
2,622
2,926
3,421
3,269
3,391
4,155
4,306
- -
Working Capital
745
866
567
248
250
945
509
1,374
1,481
1,117
1,207
1,306
1,030
631
822
854
- -
LT Debt
4,150
4,400
5,069
5,502
5,841
6,513
7,280
6,695
5,768
6,082
6,182
6,446
6,597
7,022
7,516
7,777
- -
Total Equity
9.36
6.25
12.16
13.41
16.06
14.64
14.4
12.2
9.82
9.24
7.11
8.78
7.61
10.4
11.41
9.47
- -
Return on Invested Capital (%)
9.28
6.51
12.75
14.13
16.74
15.41
14.77
11.37
9.31
9.47
7.48
9.01
7.65
10.75
11.82
9.52
- -
Return on Capital (%)
14.16
9.45
16.63
16.68
19.36
18.67
18.07
14.49
13.67
14.51
11.01
13.16
10.92
14.52
15.1
12.07
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
1,040
1,396
- -
LT Borrowings
633
840
- -
LT Finance Leases
- -
14
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
13,014
12,870
11,894

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
6,539
7,028
- -
Cash, Cash Equivalents & STI
2,312
2,778
- -
Accounts Receivable, Net
1,126
1,231
- -
Inventories
1,556
1,592
- -
Total Current Liabilities
2,543
2,722
- -
Payables & Accruals
- -
- -
- -
ST Debt
1,040
1,396
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.06%
4.71%
3.48%
Free Cash Flow
-364.03%
33.5%
-74.83%
Net Income, GAAP
-0.44%
8.54%
-15.94%
Sales/Revenue/Turnover
2.32%
5.56%
3.41%
Total Cash Common Dividend
5.44%
2.88%
7.74%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
9,952
2026
- -
- -
- -
- -
10,291
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
38.21
2026
- -
- -
- -
- -
32.12
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
21.33
2026
- -
- -
- -
- -
22.98
2027
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Daiken Medical Co., Ltd. is a Japanese medical device manufacturer specializing in the development, manufacturing, and sale of innovative medical equipment primarily focused on preventing hospital-acquired infections and managing postoperative pain. The company's core product portfolio includes suction devices; balloon type and syringe type disposable infusion pumps; endobronchial blocker tubes; wet disinfectant mats; and its proprietary COOPDECH branded products such as COOPDECH Amy PCA for postoperative pain management and COOPDECH FitFix for infection prevention. Founded in 1968 and headquartered in Nishinomiya, Japan, Daiken Medical operates mainly within the domestic Japanese market while leveraging cutting-edge technology and direct hospital relationships to drive product development and distribution. In the most recent period, Daiken Medical has demonstrated steady sales growth, notably with strong performance of COOPDECH Amy PCA and its flagship FitFix product during the first half of the fiscal year 2026. The company has managed to maintain sales growth despite a decline in earnings driven by rising material costs and increased research and development expenses, which are expected to continue into the second half of the fiscal year. Daiken Medical is actively increasing its R&D investment, targeting expansions into areas such as internal medicine and surgery to broaden its medical device offerings. The company continues to place emphasis on innovation and proprietary technology advancements to maintain its competitive edge in the medical devices sector. Daiken Medical is publicly traded on the Tokyo Stock Exchange under the ticker 7775.T. Its recent strategic focus includes reinforcing its product pipeline with next-generation infusion pumps and pain management systems, supporting home healthcare applications, and sustaining its leadership in infection control solutions. The company maintains a vertically integrated business model encompassing research, manufacturing, and direct sales to hospitals, which supports tight control over quality and market responsiveness within Japan. This approach, along with ongoing partnerships and targeted R&D, positions Daiken Medical as a key player in the Japanese medical device industry.